Cargando…
Immunotherapy of HPV-associated head and neck cancer: Critical parameters
Various arguments support the development of a vaccine targeting human papillomavirus (HPV) for the treatment of HPV-associated head and neck cancer. However, the mucosal localization of this tumor, the HPV-driven downregulation of MHC Class I molecules and various other immunosuppressive mechanisms...
Autores principales: | Nizard, Mevyn, Sandoval, Federico, Badoual, Cecile, Pere, Helene, Terme, Magali, Hans, Stephane, Benhamouda, Nadine, Granier, Clemence, Brasnu, Daniel, Tartour, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716751/ https://www.ncbi.nlm.nih.gov/pubmed/23894716 http://dx.doi.org/10.4161/onci.24534 |
Ejemplares similares
-
VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
por: Terme, Magali, et al.
Publicado: (2013) -
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer
por: Pere, Helene, et al.
Publicado: (2012) -
Induction of resident memory T cells enhances the efficacy of cancer vaccine
por: Nizard, Mevyn, et al.
Publicado: (2017) -
Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma
por: Pai, Sara I.
Publicado: (2013) -
VEGF-A modulates expression of inhibitory checkpoints on CD8(+) T cells in tumors
por: Voron, Thibault, et al.
Publicado: (2015)